A thalidomide analogue with in vitro antiproliferative, antimitotic, and microtubule-stabilizing activities
We discovered a thalidomide analogue [5-hydroxy-(2,6-diisopropylphenyl)-1H-isoindole-1,3-dione (5HPP-33)] with antiproliferative activity against nine cancer cell lines in vitro . Flow cytometric analyses showed that the compound caused G 2 -M arrest, which occurred mainly at the mitotic phase. In a...
Gespeichert in:
| Veröffentlicht in: | Molecular cancer therapeutics 2006-02, Vol.5 (2), p.450-456 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 456 |
|---|---|
| container_issue | 2 |
| container_start_page | 450 |
| container_title | Molecular cancer therapeutics |
| container_volume | 5 |
| creator | Li, Pui-Kai Pandit, Bulbul Sackett, Dan L Hu, Zhigen Zink, Jennifer Zhi, Jiandong Freeman, Dena Robey, Robert W Werbovetz, Karl Lewis, Andrew Li, Chenglong |
| description | We discovered a thalidomide analogue [5-hydroxy-(2,6-diisopropylphenyl)-1H-isoindole-1,3-dione (5HPP-33)] with antiproliferative
activity against nine cancer cell lines in vitro . Flow cytometric analyses showed that the compound caused G 2 -M arrest, which occurred mainly at the mitotic phase. In addition, immunofluorescence microscopy and in vitro tubulin polymerization studies showed that 5HPP-33 has antimicrotubule activity with a paclitaxel-like mode of action. It
is effective against four different paclitaxel-resistant cell lines. Thus, 5HPP-33 represents a potential antitumor agent.
[Mol Cancer Ther 2006;5(2):450–6] |
| doi_str_mv | 10.1158/1535-7163.MCT-05-0254 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67697219</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>19433560</sourcerecordid><originalsourceid>FETCH-LOGICAL-c369t-9a7bb57e757903baaf48ab786a446cf3a04b3e81849ede2e52a20e1e1c4cda053</originalsourceid><addsrcrecordid>eNqFUctO3TAQtaqi8uontMqqqwbs2JPHEl3RFgnUDaytiTO5GciD2s5F5eubcK_EsiuPj86ZxzlCfFHyQikoLxVoSAuV64u7zX0qIZUZmA_iZMHLtARlPr7Ve86xOA3hUUpVVpn6JI5VDhJUJk_E01USO-y5mQZuKMER-2k7U_LCsUt4THYc_bTAkZ_91HNLHiPv6PsbNHCcIrv10yQDOz_FuZ57SkPEmnt-5XGboFsEHJnCuThqsQ_0-fCeiYcf1_ebX-nt7583m6vb1Om8immFRV1DQQUUldQ1YmtKrIsyR2Ny12qUptZUqtJU1FBGkGEmSZFyxjUoQZ-Jb_u-y8p_ZgrRDhwc9T2ONM3B5kVeFZmq_ktUldEacrkQYU9cTgzBU2ufPQ_o_1ol7RqHXa22q9V2icNKsGsci-7rYcBcD9S8qw7-v2_Q8bZ7YU_W4ejIewqE3nUWbGYNSP0PsMSWSA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>19433560</pqid></control><display><type>article</type><title>A thalidomide analogue with in vitro antiproliferative, antimitotic, and microtubule-stabilizing activities</title><source>MEDLINE</source><source>American Association for Cancer Research</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Li, Pui-Kai ; Pandit, Bulbul ; Sackett, Dan L ; Hu, Zhigen ; Zink, Jennifer ; Zhi, Jiandong ; Freeman, Dena ; Robey, Robert W ; Werbovetz, Karl ; Lewis, Andrew ; Li, Chenglong</creator><creatorcontrib>Li, Pui-Kai ; Pandit, Bulbul ; Sackett, Dan L ; Hu, Zhigen ; Zink, Jennifer ; Zhi, Jiandong ; Freeman, Dena ; Robey, Robert W ; Werbovetz, Karl ; Lewis, Andrew ; Li, Chenglong</creatorcontrib><description>We discovered a thalidomide analogue [5-hydroxy-(2,6-diisopropylphenyl)-1H-isoindole-1,3-dione (5HPP-33)] with antiproliferative
activity against nine cancer cell lines in vitro . Flow cytometric analyses showed that the compound caused G 2 -M arrest, which occurred mainly at the mitotic phase. In addition, immunofluorescence microscopy and in vitro tubulin polymerization studies showed that 5HPP-33 has antimicrotubule activity with a paclitaxel-like mode of action. It
is effective against four different paclitaxel-resistant cell lines. Thus, 5HPP-33 represents a potential antitumor agent.
[Mol Cancer Ther 2006;5(2):450–6]</description><identifier>ISSN: 1535-7163</identifier><identifier>EISSN: 1538-8514</identifier><identifier>DOI: 10.1158/1535-7163.MCT-05-0254</identifier><identifier>PMID: 16505120</identifier><language>eng</language><publisher>United States: American Association for Cancer Research</publisher><subject>Animals ; antimicrotubule ; Antimitotic Agents - chemical synthesis ; Antimitotic Agents - chemistry ; Antimitotic Agents - pharmacology ; Antineoplastic Agents - chemical synthesis ; Antineoplastic Agents - chemistry ; Antineoplastic Agents - pharmacology ; Cell Cycle - drug effects ; Cell Line, Tumor ; Drug Resistance, Neoplasm ; Humans ; Indoles - chemical synthesis ; Indoles - chemistry ; Indoles - pharmacology ; Isoindoles ; Mice ; multidrug resistance ; Paclitaxel - pharmacology ; thalidomide ; tubulin ; Tubulin - drug effects ; Tubulin Modulators - chemical synthesis ; Tubulin Modulators - chemistry ; Tubulin Modulators - pharmacology</subject><ispartof>Molecular cancer therapeutics, 2006-02, Vol.5 (2), p.450-456</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c369t-9a7bb57e757903baaf48ab786a446cf3a04b3e81849ede2e52a20e1e1c4cda053</citedby><cites>FETCH-LOGICAL-c369t-9a7bb57e757903baaf48ab786a446cf3a04b3e81849ede2e52a20e1e1c4cda053</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,3356,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16505120$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Li, Pui-Kai</creatorcontrib><creatorcontrib>Pandit, Bulbul</creatorcontrib><creatorcontrib>Sackett, Dan L</creatorcontrib><creatorcontrib>Hu, Zhigen</creatorcontrib><creatorcontrib>Zink, Jennifer</creatorcontrib><creatorcontrib>Zhi, Jiandong</creatorcontrib><creatorcontrib>Freeman, Dena</creatorcontrib><creatorcontrib>Robey, Robert W</creatorcontrib><creatorcontrib>Werbovetz, Karl</creatorcontrib><creatorcontrib>Lewis, Andrew</creatorcontrib><creatorcontrib>Li, Chenglong</creatorcontrib><title>A thalidomide analogue with in vitro antiproliferative, antimitotic, and microtubule-stabilizing activities</title><title>Molecular cancer therapeutics</title><addtitle>Mol Cancer Ther</addtitle><description>We discovered a thalidomide analogue [5-hydroxy-(2,6-diisopropylphenyl)-1H-isoindole-1,3-dione (5HPP-33)] with antiproliferative
activity against nine cancer cell lines in vitro . Flow cytometric analyses showed that the compound caused G 2 -M arrest, which occurred mainly at the mitotic phase. In addition, immunofluorescence microscopy and in vitro tubulin polymerization studies showed that 5HPP-33 has antimicrotubule activity with a paclitaxel-like mode of action. It
is effective against four different paclitaxel-resistant cell lines. Thus, 5HPP-33 represents a potential antitumor agent.
[Mol Cancer Ther 2006;5(2):450–6]</description><subject>Animals</subject><subject>antimicrotubule</subject><subject>Antimitotic Agents - chemical synthesis</subject><subject>Antimitotic Agents - chemistry</subject><subject>Antimitotic Agents - pharmacology</subject><subject>Antineoplastic Agents - chemical synthesis</subject><subject>Antineoplastic Agents - chemistry</subject><subject>Antineoplastic Agents - pharmacology</subject><subject>Cell Cycle - drug effects</subject><subject>Cell Line, Tumor</subject><subject>Drug Resistance, Neoplasm</subject><subject>Humans</subject><subject>Indoles - chemical synthesis</subject><subject>Indoles - chemistry</subject><subject>Indoles - pharmacology</subject><subject>Isoindoles</subject><subject>Mice</subject><subject>multidrug resistance</subject><subject>Paclitaxel - pharmacology</subject><subject>thalidomide</subject><subject>tubulin</subject><subject>Tubulin - drug effects</subject><subject>Tubulin Modulators - chemical synthesis</subject><subject>Tubulin Modulators - chemistry</subject><subject>Tubulin Modulators - pharmacology</subject><issn>1535-7163</issn><issn>1538-8514</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFUctO3TAQtaqi8uontMqqqwbs2JPHEl3RFgnUDaytiTO5GciD2s5F5eubcK_EsiuPj86ZxzlCfFHyQikoLxVoSAuV64u7zX0qIZUZmA_iZMHLtARlPr7Ve86xOA3hUUpVVpn6JI5VDhJUJk_E01USO-y5mQZuKMER-2k7U_LCsUt4THYc_bTAkZ_91HNLHiPv6PsbNHCcIrv10yQDOz_FuZ57SkPEmnt-5XGboFsEHJnCuThqsQ_0-fCeiYcf1_ebX-nt7583m6vb1Om8immFRV1DQQUUldQ1YmtKrIsyR2Ny12qUptZUqtJU1FBGkGEmSZFyxjUoQZ-Jb_u-y8p_ZgrRDhwc9T2ONM3B5kVeFZmq_ktUldEacrkQYU9cTgzBU2ufPQ_o_1ol7RqHXa22q9V2icNKsGsci-7rYcBcD9S8qw7-v2_Q8bZ7YU_W4ejIewqE3nUWbGYNSP0PsMSWSA</recordid><startdate>20060201</startdate><enddate>20060201</enddate><creator>Li, Pui-Kai</creator><creator>Pandit, Bulbul</creator><creator>Sackett, Dan L</creator><creator>Hu, Zhigen</creator><creator>Zink, Jennifer</creator><creator>Zhi, Jiandong</creator><creator>Freeman, Dena</creator><creator>Robey, Robert W</creator><creator>Werbovetz, Karl</creator><creator>Lewis, Andrew</creator><creator>Li, Chenglong</creator><general>American Association for Cancer Research</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>20060201</creationdate><title>A thalidomide analogue with in vitro antiproliferative, antimitotic, and microtubule-stabilizing activities</title><author>Li, Pui-Kai ; Pandit, Bulbul ; Sackett, Dan L ; Hu, Zhigen ; Zink, Jennifer ; Zhi, Jiandong ; Freeman, Dena ; Robey, Robert W ; Werbovetz, Karl ; Lewis, Andrew ; Li, Chenglong</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c369t-9a7bb57e757903baaf48ab786a446cf3a04b3e81849ede2e52a20e1e1c4cda053</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Animals</topic><topic>antimicrotubule</topic><topic>Antimitotic Agents - chemical synthesis</topic><topic>Antimitotic Agents - chemistry</topic><topic>Antimitotic Agents - pharmacology</topic><topic>Antineoplastic Agents - chemical synthesis</topic><topic>Antineoplastic Agents - chemistry</topic><topic>Antineoplastic Agents - pharmacology</topic><topic>Cell Cycle - drug effects</topic><topic>Cell Line, Tumor</topic><topic>Drug Resistance, Neoplasm</topic><topic>Humans</topic><topic>Indoles - chemical synthesis</topic><topic>Indoles - chemistry</topic><topic>Indoles - pharmacology</topic><topic>Isoindoles</topic><topic>Mice</topic><topic>multidrug resistance</topic><topic>Paclitaxel - pharmacology</topic><topic>thalidomide</topic><topic>tubulin</topic><topic>Tubulin - drug effects</topic><topic>Tubulin Modulators - chemical synthesis</topic><topic>Tubulin Modulators - chemistry</topic><topic>Tubulin Modulators - pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Li, Pui-Kai</creatorcontrib><creatorcontrib>Pandit, Bulbul</creatorcontrib><creatorcontrib>Sackett, Dan L</creatorcontrib><creatorcontrib>Hu, Zhigen</creatorcontrib><creatorcontrib>Zink, Jennifer</creatorcontrib><creatorcontrib>Zhi, Jiandong</creatorcontrib><creatorcontrib>Freeman, Dena</creatorcontrib><creatorcontrib>Robey, Robert W</creatorcontrib><creatorcontrib>Werbovetz, Karl</creatorcontrib><creatorcontrib>Lewis, Andrew</creatorcontrib><creatorcontrib>Li, Chenglong</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Molecular cancer therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Li, Pui-Kai</au><au>Pandit, Bulbul</au><au>Sackett, Dan L</au><au>Hu, Zhigen</au><au>Zink, Jennifer</au><au>Zhi, Jiandong</au><au>Freeman, Dena</au><au>Robey, Robert W</au><au>Werbovetz, Karl</au><au>Lewis, Andrew</au><au>Li, Chenglong</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A thalidomide analogue with in vitro antiproliferative, antimitotic, and microtubule-stabilizing activities</atitle><jtitle>Molecular cancer therapeutics</jtitle><addtitle>Mol Cancer Ther</addtitle><date>2006-02-01</date><risdate>2006</risdate><volume>5</volume><issue>2</issue><spage>450</spage><epage>456</epage><pages>450-456</pages><issn>1535-7163</issn><eissn>1538-8514</eissn><abstract>We discovered a thalidomide analogue [5-hydroxy-(2,6-diisopropylphenyl)-1H-isoindole-1,3-dione (5HPP-33)] with antiproliferative
activity against nine cancer cell lines in vitro . Flow cytometric analyses showed that the compound caused G 2 -M arrest, which occurred mainly at the mitotic phase. In addition, immunofluorescence microscopy and in vitro tubulin polymerization studies showed that 5HPP-33 has antimicrotubule activity with a paclitaxel-like mode of action. It
is effective against four different paclitaxel-resistant cell lines. Thus, 5HPP-33 represents a potential antitumor agent.
[Mol Cancer Ther 2006;5(2):450–6]</abstract><cop>United States</cop><pub>American Association for Cancer Research</pub><pmid>16505120</pmid><doi>10.1158/1535-7163.MCT-05-0254</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1535-7163 |
| ispartof | Molecular cancer therapeutics, 2006-02, Vol.5 (2), p.450-456 |
| issn | 1535-7163 1538-8514 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_67697219 |
| source | MEDLINE; American Association for Cancer Research; EZB-FREE-00999 freely available EZB journals |
| subjects | Animals antimicrotubule Antimitotic Agents - chemical synthesis Antimitotic Agents - chemistry Antimitotic Agents - pharmacology Antineoplastic Agents - chemical synthesis Antineoplastic Agents - chemistry Antineoplastic Agents - pharmacology Cell Cycle - drug effects Cell Line, Tumor Drug Resistance, Neoplasm Humans Indoles - chemical synthesis Indoles - chemistry Indoles - pharmacology Isoindoles Mice multidrug resistance Paclitaxel - pharmacology thalidomide tubulin Tubulin - drug effects Tubulin Modulators - chemical synthesis Tubulin Modulators - chemistry Tubulin Modulators - pharmacology |
| title | A thalidomide analogue with in vitro antiproliferative, antimitotic, and microtubule-stabilizing activities |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T07%3A34%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20thalidomide%20analogue%20with%20in%20vitro%20antiproliferative,%20antimitotic,%20and%20microtubule-stabilizing%20activities&rft.jtitle=Molecular%20cancer%20therapeutics&rft.au=Li,%20Pui-Kai&rft.date=2006-02-01&rft.volume=5&rft.issue=2&rft.spage=450&rft.epage=456&rft.pages=450-456&rft.issn=1535-7163&rft.eissn=1538-8514&rft_id=info:doi/10.1158/1535-7163.MCT-05-0254&rft_dat=%3Cproquest_cross%3E19433560%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=19433560&rft_id=info:pmid/16505120&rfr_iscdi=true |